Clinical Trial Update: Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis [Phase 4]

View source ↗

Summary

Phase 4 trial update on methotrexate withdrawal in rheumatoid arthritis patients treated with tofacitinib modified-release formulation; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• METHOTREXATE (METHOTREXATE)
• tofacitinib modified release (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Rheumatoid Arthritis | Phase 4 | Status: COMPLETED | Results posted: 2019-12-04